Biopharmx Corp Company Profile (NYSE:BPMX)

About Biopharmx Corp (NYSE:BPMX)

Biopharmx Corp logoBioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women's health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia. Its VI2OLET is an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort and is clinically demonstrated to alleviate the symptoms associated with FBC, including tenderness, aches and swelling. It is developing BPX02, which is an injectable utilizing biologic materials for aesthetic dermatology applications.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NYSE:BPMX
  • CUSIP: N/A
  • Web: www.biopharmx.com
Capitalization:
  • Market Cap: $22.43 million
  • Outstanding Shares: 79,669,000
Average Prices:
  • 50 Day Moving Avg: $0.30
  • 200 Day Moving Avg: $0.45
  • 52 Week Range: $0.19 - $0.90
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.72
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: $83,999.00
  • Price / Sales: 266.99
  • Book Value: ($0.01) per share
  • Price / Book: -56.30
Profitability:
  • EBITDA: ($18,070,000.00)
  • Net Margins: -22,005.88%
  • Return on Equity: -5,749.08%
  • Return on Assets: -240.31%
Misc:
  • Average Volume: 922,400 shs.
  • Short Ratio: 4.6
 

Frequently Asked Questions for Biopharmx Corp (NYSE:BPMX)

What is Biopharmx Corp's stock symbol?

Biopharmx Corp trades on the New York Stock Exchange (NYSE) under the ticker symbol "BPMX."

How were Biopharmx Corp's earnings last quarter?

Biopharmx Corp (NYSE:BPMX) announced its quarterly earnings results on Tuesday, June, 14th. The company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.01. Biopharmx Corp had a negative net margin of 22,005.88% and a negative return on equity of 5,749.08%. View Biopharmx Corp's Earnings History.

When will Biopharmx Corp make its next earnings announcement?

Biopharmx Corp is scheduled to release their next quarterly earnings announcement on Tuesday, December, 12th 2017. View Earnings Estimates for Biopharmx Corp.

Where is Biopharmx Corp's stock going? Where will Biopharmx Corp's stock price be in 2017?

1 equities research analysts have issued 1 year target prices for Biopharmx Corp's shares. Their forecasts range from $3.00 to $3.00. On average, they anticipate Biopharmx Corp's stock price to reach $3.00 in the next year. View Analyst Ratings for Biopharmx Corp.

Are investors shorting Biopharmx Corp?

Biopharmx Corp saw a increase in short interest in September. As of September 29th, there was short interest totalling 4,147,107 shares, an increase of 2.1% from the September 15th total of 4,060,605 shares. Based on an average trading volume of 1,362,369 shares, the days-to-cover ratio is currently 3.0 days. Approximately 7.2% of the company's shares are sold short.

Who are some of Biopharmx Corp's key competitors?

Who are Biopharmx Corp's key executives?

Biopharmx Corp's management team includes the folowing people:

  • James R. Pekarsky, Chairman of the Board, Chief Executive Officer
  • Anja B. Krammer, President, Director
  • Gregory David Kitchener, Chief Financial Officer, Executive Vice President - Finance
  • Kin F. Chan Ph.D., Executive Vice President - Research & Development
  • AnnaMarie Daniels, Executive Vice President - Clinical and Regulatory Affairs
  • Stephen Morlock, Independent Director
  • Charles Gregory Vontz, Independent Director
  • Ping Wang, Independent Director

How do I buy Biopharmx Corp stock?

Shares of Biopharmx Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biopharmx Corp's stock price today?

One share of Biopharmx Corp stock can currently be purchased for approximately $0.28.


MarketBeat Community Rating for Biopharmx Corp (NYSE BPMX)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  82 (Vote Outperform)
Underperform Votes:  36 (Vote Underperform)
Total Votes:  118
MarketBeat's community ratings are surveys of what our community members think about Biopharmx Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Biopharmx Corp (NYSE:BPMX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.00 (965.72% upside)
Consensus Price Target History for Biopharmx Corp (NYSE:BPMX)
Price Target History for Biopharmx Corp (NYSE:BPMX)
Analysts' Ratings History for Biopharmx Corp (NYSE:BPMX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
2/9/2017Roth CapitalSet Price TargetBuy$3.00N/AView Rating Details
9/17/2016HC WainwrightReiterated RatingBuyN/AView Rating Details
4/15/2016Maxim GroupInitiated CoverageBuy$3.00N/AView Rating Details
(Data available from 10/18/2015 forward)

Earnings

Earnings History for Biopharmx Corp (NYSE:BPMX)
Earnings by Quarter for Biopharmx Corp (NYSE:BPMX)
Earnings History by Quarter for Biopharmx Corp (NYSE BPMX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/12/2017        
12/13/2016Q3 2017($0.15)($0.13)ViewN/AView Earnings Details
6/14/2016Q117($0.17)($0.16)ViewListenView Earnings Details
4/26/2016Q416($0.17)($0.18)ViewListenView Earnings Details
12/14/2015Q316($0.19)($0.17)ViewN/AView Earnings Details
9/14/2015Q216($0.29)($0.22)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Biopharmx Corp (NYSE:BPMX)
Current Year EPS Consensus Estimate: $-0.2400 EPS
Next Year EPS Consensus Estimate: $-0.3900 EPS

Dividends

Dividend History for Biopharmx Corp (NYSE:BPMX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Biopharmx Corp (NYSE:BPMX)
Insider Trades by Quarter for Biopharmx Corp (NYSE:BPMX)
Insider Trades by Quarter for Biopharmx Corp (NYSE:BPMX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/28/2016Stephen MorlockDirectorBuy428,571$0.35$149,999.85View SEC Filing  
8/15/2016Franklin Resources IncMajor ShareholderBuy484,615$0.65$314,999.75View SEC Filing  
3/29/2016Franklin Resources IncMajor ShareholderBuy540,000$1.20$648,000.00View SEC Filing  
1/14/2016Stephen MorlockDirectorBuy12,000$1.52$18,240.00View SEC Filing  
1/12/2016Stephen MorlockDirectorBuy6,000$1.53$9,180.00View SEC Filing  
1/7/2016Stephen MorlockDirectorBuy5,000$1.47$7,350.00View SEC Filing  
10/15/2015Stephen MorlockDirectorBuy5,000$1.24$6,200.00View SEC Filing  
10/9/2015Stephen MorlockDirectorBuy3,000$1.21$3,630.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Biopharmx Corp (NYSE:BPMX)
Latest Headlines for Biopharmx Corp (NYSE:BPMX)
Source:
DateHeadline
americanbankingnews.com logoBiopharmx Corp (BPMX) Expected to Post Quarterly Sales of $20,000.00
www.americanbankingnews.com - October 16 at 3:38 AM
americanbankingnews.com logoBiopharmx Corp (BPMX) Expected to Post Earnings of -$0.06 Per Share
www.americanbankingnews.com - October 14 at 12:34 PM
finance.yahoo.com logoBioPharmX Collaborates with Wellman Center for Photomedicine to Develop Pioneering, Cost-Effective Technique to Visualize Drug Delivery
finance.yahoo.com - October 11 at 6:11 PM
finance.yahoo.com logoETFs with exposure to BioPharmX Corp. : October 10, 2017
finance.yahoo.com - October 10 at 5:57 PM
americanbankingnews.com logoBiopharmx Corp (BPMX) Short Interest Update
www.americanbankingnews.com - October 10 at 5:20 PM
finance.yahoo.com logoIs BioPharmX Corporation (BPMX) Still A Cheap Healthcare Stock?
finance.yahoo.com - October 2 at 1:52 PM
americanbankingnews.com logo$30,000.00 in Sales Expected for Biopharmx Corp (BPMX) This Quarter
www.americanbankingnews.com - September 27 at 5:06 AM
americanbankingnews.com logoShort Interest in Biopharmx Corp (BPMX) Decreases By 5.7%
www.americanbankingnews.com - September 27 at 1:18 AM
americanbankingnews.com logo Biopharmx Corp (BPMX) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - September 19 at 2:38 AM
finance.yahoo.com logoBioPharmX Corp. :BPMX-US: Earnings Analysis: Q2, 2018 By the Numbers : September 14, 2017
finance.yahoo.com - September 14 at 5:23 PM
prnewswire.com logoBioPharmX Reports Second Quarter 2018 Financial Results - PR Newswire (press release)
www.prnewswire.com - September 13 at 10:53 PM
seekingalpha.com logoBioPharmX (BPMX) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 5:52 PM
finance.yahoo.com logoBioPharmX Reports Second Quarter 2018 Financial Results
finance.yahoo.com - September 13 at 5:52 PM
americanbankingnews.com logoBiopharmx Corp (BPMX) Short Interest Down 2.9% in August
www.americanbankingnews.com - September 13 at 1:26 AM
streetinsider.com logoBioPharmX (BPMX) Says Preliminary Data from Ongoing Rosacea ... - StreetInsider.com
www.streetinsider.com - September 12 at 10:13 PM
americanbankingnews.com logo$20,000.00 in Sales Expected for Biopharmx Corp (BPMX) This Quarter
www.americanbankingnews.com - September 9 at 5:32 PM
finance.yahoo.com logoBioPharmX to Present at Rodman & Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - September 5 at 6:17 PM
americanbankingnews.com logo Analysts Set $3.38 Price Target for Biopharmx Corp (BPMX)
www.americanbankingnews.com - August 31 at 12:30 PM
americanbankingnews.com logo Biopharmx Corp (BPMX) Given Consensus Rating of "" by Analysts
www.americanbankingnews.com - August 28 at 12:44 AM
americanbankingnews.com logo Brokerages Expect Biopharmx Corp (BPMX) Will Announce Quarterly Sales of $20,000.00
www.americanbankingnews.com - August 21 at 5:08 AM
americanbankingnews.com logoBiopharmx Corp (NYSE:BPMX) Sees Significant Drop in Short Interest
www.americanbankingnews.com - August 10 at 7:54 AM
americanbankingnews.com logo Brokerages Set $3.38 Price Target for Biopharmx Corp (NYSE:BPMX)
www.americanbankingnews.com - August 8 at 7:44 AM
americanbankingnews.com logo Analysts Expect Biopharmx Corp (NYSE:BPMX) Will Announce Quarterly Sales of $20,000.00
www.americanbankingnews.com - August 3 at 7:52 AM
americanbankingnews.com logo Brokerages Expect Biopharmx Corp (BPMX) Will Post Earnings of -$0.07 Per Share
www.americanbankingnews.com - August 1 at 8:18 AM
prnewswire.com logoSummer AAD Panel to Discuss BPX-01 for Acne and Rosacea - PR Newswire (press release)
www.prnewswire.com - July 27 at 5:12 PM
americanbankingnews.com logo Biopharmx Corp (BPMX) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - July 24 at 9:14 AM
americanbankingnews.com logoBrokerages Expect Biopharmx Corp (BPMX) to Post ($0.07) EPS
www.americanbankingnews.com - July 18 at 4:56 PM
prnewswire.com logoBioPharmX To Present Phase 2b Clinical Trial Data at National DEF Essential Resource Meeting 2017 - PR Newswire (press release)
www.prnewswire.com - July 13 at 10:49 PM
finance.yahoo.com logoBioPharmX To Present Phase 2b Clinical Trial Data at National DEF Essential Resource Meeting 2017
finance.yahoo.com - July 13 at 5:45 PM
americanbankingnews.com logoBiopharmx Corp (NYSE:BPMX) Short Interest Update
www.americanbankingnews.com - July 13 at 7:00 AM
finance.yahoo.com logoETFs with exposure to BioPharmX Corp. : July 12, 2017
finance.yahoo.com - July 12 at 5:17 PM
benzinga.com logoExclusive: Biopharmx CFO Talks Trial Results, Competitive Prospects For BPMX Acne Treatment - Benzinga
www.benzinga.com - May 8 at 3:54 PM
streetinsider.com logoBioPharmX (BPMX) Phase 2b Trail of BPX-01 Topical Minocycline for Acne Achieves Primary Endpoint; Secondary ... - StreetInsider.com
www.streetinsider.com - May 3 at 9:06 PM
streetinsider.com logoBioPharmX (BPMX) Expects Topline Results from Phase 2b Trial of BPX-01 in First Half of May 2017 - StreetInsider.com
www.streetinsider.com - April 20 at 4:08 PM
benzinga.com logoBioPharmX CFO Talks Clinical Pipeline Ahead Of Big Q2 Catalyst - Benzinga
www.benzinga.com - March 31 at 4:08 PM
us.rd.yahoo.com logoBioPharmX AACR Poster Will Present Findings Suggesting Molecular Iodine Inhibits Breast Cancer Cell Growth and Drives Cancer Cell Death
us.rd.yahoo.com - March 30 at 4:24 PM
biz.yahoo.com logoBIOPHARMX CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - March 29 at 4:21 PM
seekingalpha.com logoBioPharmX Has A Major Upcoming Catalyst
seekingalpha.com - March 27 at 3:58 PM

Social

Chart

Biopharmx Corp (BPMX) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.